Analyst Ratings for Hospira (HSP)
HSP Rating Summary
HSP Price Target Summary
- Highest: $42.00 (Dougherty & Co)
- Lowest: $30.00 (Leerink Swann)
- Average: $34.78
Overall Rating:
NEUTRAL
Rating Trend:
Avg. $ Target:
$34.78 (-3.2%)
Avg. $ Target:
$34.78 (-3.2%)
| Date | Firm | Type | Rating (Past) |
PT (Past) |
Start $ | End $ | % Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 5/2/2013 | Raymond James | Downgrade | Underperform (Market Perform) |
N/A (N/A) |
32.10 | 35.92 | 11.9% | Details |
| 3/8/2013 | UBS | Upgrade | Neutral (Sell) |
30.00 (28.00) |
29.66 | 35.92 | 21.11% | Details |
| 2/26/2013 | Gabelli | Downgrade | Hold (Buy) |
N/A (N/A) |
29.11 | 35.92 | 23.39% | Details |
| 2/13/2013 | BofA/Merrill Lynch | Downgrade | Neutral (Buy) |
N/A (N/A) |
34.95 | 35.92 | 2.78% | Details |
| 8/9/2012 | JPMorgan | Downgrade | Neutral (Overweight) |
38.00 (40.00) |
34.59 | 35.92 | 3.85% | Details |
| 4/18/2012 | Dougherty & Co | New Coverage | Buy (N/A) |
42.00 (N/A) |
34.99 | 35.92 | 2.66% | Details |
| 2/17/2012 | Citi | Downgrade | Sell (N/A) |
33.00 (N/A) |
37.92 | 35.92 | -5.27% | Details |
| 12/19/2011 | Bernstein | Downgrade | Market Perform (N/A) |
32.00 (N/A) |
28.92 | 35.92 | 24.2% | Details |
| 10/19/2011 | Capstone Investments | Downgrade | Hold (N/A) |
37.00 (N/A) |
29.51 | 35.92 | 21.72% | Details |
| 10/18/2011 | Ticonderoga | Downgrade | Neutral (N/A) |
N/A (N/A) |
29.54 | 35.92 | 21.6% | Details |
| 10/18/2011 | Buckingham Research | Downgrade | Neutral (N/A) |
N/A (N/A) |
29.62 | 35.92 | 21.27% | Details |
| 10/18/2011 | Leerink Swann | Downgrade | Market Perform (N/A) |
30.00 (N/A) |
37.36 | 35.92 | -3.85% | Details |
| 9/13/2011 | Barclays » Updated 2/16/2012 |
Downgrade | Equalweight (N/A) |
36.00 (N/A) |
40.59 | 35.92 | -11.51% | Details |
| 5/11/2011 | Goldman Sachs | Downgrade | Neutral (N/A) |
N/A (N/A) |
56.94 | 35.92 | -36.92% | Details |
| 2/14/2011 | Collins Stewart » Updated 10/19/2011 |
New Coverage | Buy (N/A) |
35.00 (N/A) |
54.26 | 35.92 | -33.8% | Details |
